Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2238-2245

  Holderfield, Matthew ^a   Lorenzana, Edward ^a   Weisburd, Ben ^a   Lomovasky, Lisa ^a   Boussemart, Lise ^c   Lacroix, Ludovic ^d,e   Tomasic, Gorana ^d,e,f   Favre, Michel ^g   Vagner, Stephan ^f   Robert, Caroline ^c   Ghoddusi, Majid ^a   Daniel, Dylan ^a   Pryer, Nancy ^a   McCormick, Frank ^b   Stuart, Darrin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Universite Paris Sud   (France)

^d Department of Medical Biology and Pathology ^*  (France)

^e Laboratory and Biobank   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; DUAL SPECIFICITY PHOSPHATASE 6; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN CARCINOMA; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; EARLY DETECTION OF CANCER; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INDOLES; KERATIN-14; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84899559516     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1065-T     Document Type: Article

References (33)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
4. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-e61.
5. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu- Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.
6. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
7. Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, et al. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther 2010;9:2399-410.
8. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140: 209-21.
9. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
10. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, et al. RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. Cancer Cell 2013;23:594-602.
11. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-21.
12. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 2012;18:263-72.
13. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
14. Coussens LM, Hanahan D, Arbeit JM. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 1996;149:1899-917.
15. Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999;80:2437-43.
16. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998;110:311-7.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483: 603-7.
18. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 2009;25:1754-60.
19. Depristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using nextgeneration DNA sequencing data. Nat Genet 2011;43:491-8.
20. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-11.
21. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009;106:4519-24.
22. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-60.
23. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013; 149:322-6.
24. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
25. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005;65:1394-400.
26. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131:1745-53.
27. Marcuzzi GP, Hufbauer M, Kasper HU, Weissenborn SJ, Smola S, Pfister H. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol 2009;90:2855-64.
28. Aldabagh B, Angeles JG, Cardones AR, Arron ST. Cutaneous Squamous Cell Carcinoma and Human Papillomavirus: Is There an Association? Dermatol Surg 2012;39:1-23.
29. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 2012;67: 1265-72.
30. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012;148:628-33.
31. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2012;24:530-7.
32. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-e18.
33. Ascierto PA, Bastholt L, Hersey PF, Cinat GF, Eggermont AM, Hauschild A, et al. Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. Am J Ther 2013 Oct 31. [Epub ahead of print].